—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Spyre Therapeutics Inc. (SYRE) — Technical state

As of 2026-11-02 — re-computed nightly across the coverage universe. Closelooknet diary readings, not advice.

The Closelooknet read

  • Closelooknet score: 27 out of 100 (momentum 80 · quality 3 · valuation 8), as of 2026-11-03.
  • Signal: Uptrend stack intact — Trades +6.3% vs the 50-day and +29.9% vs the 200-day average, 13.3% below the 52-week high and +351.7% off the 52-week low. Computed from daily closes. (as of 2026-11-02)
  • Trend: Spyre Therapeutics Inc. trades 6.3% above its 50-day and 29.9% above its 200-day moving average. (as of 2026-11-02)

Spyre Therapeutics is a clinical-stage biotechnology company that develops antibody treatments for inflammatory bowel disease and rheumatic conditions. Its lead candidate targets the a4ß7 integrin for ulcerative colitis and Crohn's disease, alongside separate antibodies aimed at TL1A and IL-23, some combined into dual-target programmes.

The full read — the desk's view, the earnings record, peers and the company snapshot — is on the SYRE overview. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Uptrend stack intact

Trades +6.3% vs the 50-day and +29.9% vs the 200-day average, 13.3% below the 52-week high and +351.7% off the 52-week low. Computed from daily closes.

Ranked #23 on today’s Directional Flow — Top scores list (scan of 2026-11-02).

The moving-average stack

Continue: the SYRE chart & overview · quality & forensics · the earnings record · the signal board

FAQ · from the current data · as of 2026-11-02

Quick answers

What is the current Closelooknet signal on SYRE?

Uptrend stack intact — Trades +6.3% vs the 50-day and +29.9% vs the 200-day average, 13.3% below the 52-week high and +351.7% off the 52-week low. Computed from daily closes. As of 2026-11-02; the signal board re-computes across the coverage universe nightly. A research diary reading, not advice.

Is SYRE above its 50-day and 200-day moving averages?

As of 2026-11-02, Spyre Therapeutics Inc. trades +6.3% above its 50-day and +29.9% above its 200-day average, with the 20-day +8.2% away.

How far is SYRE from its 52-week high?

13.3% below the 52-week high and 351.7% above the 52-week low, as of 2026-11-02.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.